Skip to main content

Table 5 Course of clinical signs and symptoms from initial to last follow up visit (efficacy population)

From: Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)

Course of symptoms

Dyspnea

Cough

Sputum character

Thoracic pain

Auscultation

Temperature*

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

n

(%)

Total

2152

(100.0)

2152

(100.0)

2152

(100.0)

2152

(100.0)

2152

(100.0)

2152

(100.0)

Relieved

1677

(77.9)

1174

(54.6)

1343

(62.4)

1914

(88.9)

1811

(84.2)

722

(33.6)

Improved

374

(17.4)

832

(38.7)

695

(32.3)

148

(6.9)

0

(-)

1101

(51.2)

Unchanged

61

(2.8)

104

(4.8)

65

(3.0)

45

(2.1)

253

(11.8)

98

(4.6)

Worsened

9

(0.4)

13

(0.6)

21

(1.0)

10

(0.5)

2

(0.1)

28

(1.3)

Missing

31

(1.4)

29

(1.3)

28

(1.3)

35

(1.6)

86

(4.0)

203

(9.4)

  1. *Comparison of temperature ranges: Low: <36.0°C, Normal: 36.0°C – <37.5°C, Mild: 37.5°C – <38.0°C, Moderate: 38.0°C – <39.0°C, Severe: ≥39.0°C.